Overview

Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection

Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral drugs. Cal-1 is an experimental gene transfer agent designed to inhibit HIV infection through 2 active parts: 1. Removing a protein named CCR5 from bone marrow and white blood cells 2. Producing a protein named C46 on bone marrow and white blood cells
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Calimmune, Inc.
Treatments:
Busulfan